Over the past decade, cancer mortality rates have declined with the adoption of personalized medicine and immuno-oncology. Flexus, an immuno-oncology pioneer, was acquired by Bristol Myers Squibb in 2015, less than 24 months after the company was incubated by Kleiner Perkins. The lead Flexus program is now in Phase 3 clinical testing for lung and renal cancer, melanoma, and other indications. Harnessing the immune system to kill rogue cells is changing the face of cancer care—and extending lives.
Kleiner Perkins is committed to respecting and protecting your privacy; please contact [email protected] with any questions regarding our privacy practices.